119 related articles for article (PubMed ID: 35788404)
1. Safety Implications of Switching Pembrolizumab Dosage From 200 mg Every 3 Weeks to 400 mg Every 6 Weeks in Patients With Advanced NSCLC.
Higashiyama RI; Yoshida T; Yagishita S; Ohuchi M; Sakiyama N; Torasawa M; Shirasawa M; Masuda K; Shinno Y; Matsumoto Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Hamada A; Ohe Y
J Thorac Oncol; 2022 Oct; 17(10):1227-1232. PubMed ID: 35788404
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab Every 6 Weeks Versus Every 3 Weeks in Advanced Non-Small Cell Lung Cancer.
Dubé-Pelletier M; Labbé C; Côté J; Pelletier-St-Pierre AA
Oncologist; 2023 Nov; 28(11):969-977. PubMed ID: 37364568
[TBL] [Abstract][Full Text] [Related]
3. Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥ 50%: 3 Weekly Compared to 6 Weekly Dosing.
Jones L; Rittberg R; Leung B; Shokoohi A; Pender A; Wong S; Al-Hashami Z; Wang Y; Ho C
Curr Oncol; 2022 Nov; 29(11):8686-8692. PubMed ID: 36421338
[TBL] [Abstract][Full Text] [Related]
4. Systematic evaluation of pembrolizumab dosing in patients with advanced non-small-cell lung cancer.
Chatterjee M; Turner DC; Felip E; Lena H; Cappuzzo F; Horn L; Garon EB; Hui R; Arkenau HT; Gubens MA; Hellmann MD; Dong D; Li C; Mayawala K; Freshwater T; Ahamadi M; Stone J; Lubiniecki GM; Zhang J; Im E; De Alwis DP; Kondic AG; Fløtten Ø
Ann Oncol; 2016 Jul; 27(7):1291-8. PubMed ID: 27117531
[TBL] [Abstract][Full Text] [Related]
5. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation.
Lala M; Li TR; de Alwis DP; Sinha V; Mayawala K; Yamamoto N; Siu LL; Chartash E; Aboshady H; Jain L
Eur J Cancer; 2020 May; 131():68-75. PubMed ID: 32305010
[TBL] [Abstract][Full Text] [Related]
6. Comparison of three-weekly and six-weekly pembrolizumab United Kingdom prescribing practice for advanced and resected melanoma.
Mehta I; Dayimu A; Kumar S; Boobier C; Oladipo O; Burke D; Olson-Brown A; Yesildag P; Nobes J; Brown S; Booth C; Wheater M; Muller D; Fountain V; Ford L; Board R; McGurk L; Twelves S; Demiris N; Corrie P
Eur J Cancer; 2023 Nov; 194():113344. PubMed ID: 37804771
[TBL] [Abstract][Full Text] [Related]
7. Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial.
Hui R; Garon EB; Goldman JW; Leighl NB; Hellmann MD; Patnaik A; Gandhi L; Eder JP; Ahn MJ; Horn L; Felip E; Carcereny E; Rangwala R; Lubiniecki GM; Zhang J; Emancipator K; Roach C; Rizvi NA
Ann Oncol; 2017 Apr; 28(4):874-881. PubMed ID: 28168303
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.
Perets R; Bar J; Rasco DW; Ahn MJ; Yoh K; Kim DW; Nagrial A; Satouchi M; Lee DH; Spigel DR; Kotasek D; Gutierrez M; Niu J; Siddiqi S; Li X; Cyrus J; Chackerian A; Chain A; Altura RA; Cho BC
Ann Oncol; 2021 Mar; 32(3):395-403. PubMed ID: 33276076
[TBL] [Abstract][Full Text] [Related]
9. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
[TBL] [Abstract][Full Text] [Related]
10. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
11. Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial.
Shaverdian N; Lisberg AE; Bornazyan K; Veruttipong D; Goldman JW; Formenti SC; Garon EB; Lee P
Lancet Oncol; 2017 Jul; 18(7):895-903. PubMed ID: 28551359
[TBL] [Abstract][Full Text] [Related]
12. A Multicentre Retrospective Analysis of Toxicity in 6-weekly Versus 3-weekly Pembrolizumab.
Rowe M; Eastlake L; Norris T; Farley T; Talbot T
J Immunother; 2021 May; 44(4):175-178. PubMed ID: 33492031
[TBL] [Abstract][Full Text] [Related]
13. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
14. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.
Nosaki K; Saka H; Hosomi Y; Baas P; de Castro G; Reck M; Wu YL; Brahmer JR; Felip E; Sawada T; Noguchi K; Han SR; Piperdi B; Kush DA; Lopes G
Lung Cancer; 2019 Sep; 135():188-195. PubMed ID: 31446994
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan Study.
Horinouchi H; Nogami N; Saka H; Nishio M; Tokito T; Takahashi T; Kasahara K; Hattori Y; Ichihara E; Adachi N; Noguchi K; Souza F; Kurata T
Cancer Sci; 2021 Aug; 112(8):3255-3265. PubMed ID: 34036692
[TBL] [Abstract][Full Text] [Related]
18. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
[TBL] [Abstract][Full Text] [Related]
19. Improved survival and disease control following pembrolizumab-induced immune-related adverse events in high PD-L1 expressing non-small cell lung cancer with brain metastases.
Zhang M; Rodrigues AJ; Pollom EL; Gibbs IC; Soltys SG; Hancock SL; Neal JW; Padda SK; Ramchandran KJ; Wakelee HA; Chang SD; Lim M; Hayden Gephart M; Li G
J Neurooncol; 2021 Mar; 152(1):125-134. PubMed ID: 33415659
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
